Company Active LTD

Company profile

Genomic Labs Ltd

GenomeKey - Unlocking DNA

Using whole genome sequencing and novel machine learning, GenomeKey diagnoses bacterial presence, species and antimicrobial resistance in only hours, not days, at low cost.

CRN
12151270
Founded
2019
Age
6

Overview

Legal name
GENOMIC LABS LTD
Region
South West England
Registered address
SCIENCE CREATES OLD MARKET LAB 09
MIDLAND ROAD
BRISTOL
UNITED KINGDOM
BS2 0JZ
Insolvency history
No

Latest accounts

Financial period: 1 Sep 2024 to 31 Aug 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
24

Company events

Reference milestones and recent Companies House filing stream events.

9 events
31 May
2027

Accounts due

Accounts Due

Next accounts due date

25 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Aug
2025

Accounts filed

Accounts

Last accounts made up date

11 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 Nov
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQ0NDI0NjcyMmFkaXF6a2N4

Published 20 Nov 2024 08:58

20 Nov
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQ0NDMwOTQ2MWFkaXF6a2N4

Published 20 Nov 2024 05:46

20 Nov
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQ0NDMwOTI4MGFkaXF6a2N4

Published 20 Nov 2024 05:42

16 Aug
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzMjUwMjg5NGFkaXF6a2N4

Published 16 Aug 2024 13:20

12 Aug
2019

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2021
Funded years
2021, 2022, 2023, 2025
Age at first award
1 years

Projects

2025 Collaborative R&D Lead participant

Continuous Contamination Monitoring through Single-Cell Sequencing for Pharmaceutical Quality Control: Fast-track to Pilot Deployment

1 Jul 2025 to 28 Feb 2026

Awarded
£346,039
Total cost £494,341

GenomeKey is developing a revolutionary environmental monitoring system for pharmaceutical manufacturing that combines proprietary microfluidic concentration technology with next-generation DNA sequencing to enable rapid detection and identification of microbial contaminants. Current pharmaceutical quality control relies on traditional culture-based testi...

2023 Collaborative R&D Lead participant

Fighting antimicrobial resistant infections - A next-generation diagnostic device

1 Jul 2023 to 30 Jun 2025

Awarded
£1,491,850
Total cost £2,131,215

GenomeKey is developing a next-generation diagnostic device for bacterial blood infections. Our diagnostic will result in earlier and more accurate detection and diagnosis of bacterial sepsis, and faster antimicrobial susceptibility results, leading to better treatment, patient outcomes and considerable treatment cost savings. In addition, our device will...

2022 Collaborative R&D Lead participant

Combatting Antimicrobial Resistance with Next-Generation Diagnostics for Sepsis

1 May 2022 to 31 Oct 2023

Awarded
£668,559
Total cost £955,081

GenomeKey is developing a next-generation point-of-care diagnostic device for bacterial blood infections in cases of sepsis. Our diagnostic will result in earlier and more accurate detection and diagnosis of bacterial sepsis, and faster antimicrobial susceptibility results, leading to better treatment, patient outcomes and considerable treatment cost savi...

2021 Collaborative R&D Lead participant

Next-generation Diagnostics for Bacterial Co-infection of COVID-19

1 Jan 2021 to 31 Mar 2021

Awarded
£101,310
Total cost £126,637

GenomeKey determines how to treat Sepsis in hours, rather than days. This is important because Sepsis now kills more people than cancer, and can kill within hours. For a patient admitted to a hospital today, they would wait 3 days before the doctor knows which antibiotic will fight the infection. GenomeKey reduces this time using cutting edge machine lear...

Product types

Collaborative R&D